vs
Side-by-side financial comparison of EQUITY BANCSHARES INC (EQBK) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $63.5M, roughly 1.5× EQUITY BANCSHARES INC). EQUITY BANCSHARES INC runs the higher net margin — 34.8% vs 25.0%, a 9.8% gap on every dollar of revenue. On growth, EQUITY BANCSHARES INC posted the faster year-over-year revenue change (28.4% vs 23.3%). EQUITY BANCSHARES INC produced more free cash flow last quarter ($38.1M vs $12.8M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 6.6%).
Prosperity Bancshares, Inc. is a bank holding company headquartered in Houston, Texas with operations in Texas and central Oklahoma. As of December 31, 2019, the company operated 285 branches: 65 in the Houston area, including The Woodlands, Texas; 30 in South Texas, including Corpus Christi, Texas and Victoria, Texas; 75 in the Dallas–Fort Worth metroplex; 22 in East Texas; 29 in Central Texas, including Austin, Texas and San Antonio; 34 in West Texas, including Lubbock, Texas, Midland–Odess...
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
EQBK vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $63.5M | $92.9M |
| Net Profit | $22.1M | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | 41.7% | 24.1% |
| Net Margin | 34.8% | 25.0% |
| Revenue YoY | 28.4% | 23.3% |
| Net Profit YoY | 30.0% | 17.3% |
| EPS (diluted) | $1.07 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $63.5M | $92.9M | ||
| Q3 25 | $18.0M | $67.5M | ||
| Q2 25 | $58.4M | $63.2M | ||
| Q1 25 | $60.6M | $52.6M | ||
| Q4 24 | $58.3M | $75.4M | ||
| Q3 24 | $55.3M | $57.9M | ||
| Q2 24 | $55.4M | $52.7M | ||
| Q1 24 | $55.9M | $51.3M |
| Q4 25 | $22.1M | $23.2M | ||
| Q3 25 | $-29.7M | $5.1M | ||
| Q2 25 | $15.3M | $-553.0K | ||
| Q1 25 | $15.0M | $-11.2M | ||
| Q4 24 | $17.0M | $19.8M | ||
| Q3 24 | $19.9M | $-901.0K | ||
| Q2 24 | $11.7M | $-4.7M | ||
| Q1 24 | $14.1M | $-3.9M |
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% | ||
| Q1 24 | — | 68.9% |
| Q4 25 | 41.7% | 24.1% | ||
| Q3 25 | -207.2% | 5.1% | ||
| Q2 25 | 31.5% | -3.2% | ||
| Q1 25 | 31.1% | -24.3% | ||
| Q4 24 | 35.0% | 24.5% | ||
| Q3 24 | 43.1% | -4.3% | ||
| Q2 24 | 29.4% | -11.5% | ||
| Q1 24 | 31.8% | -10.7% |
| Q4 25 | 34.8% | 25.0% | ||
| Q3 25 | -164.7% | 7.5% | ||
| Q2 25 | 26.1% | -0.9% | ||
| Q1 25 | 24.8% | -21.4% | ||
| Q4 24 | 29.1% | 26.3% | ||
| Q3 24 | 35.9% | -1.6% | ||
| Q2 24 | 21.1% | -8.9% | ||
| Q1 24 | 25.2% | -7.5% |
| Q4 25 | $1.07 | $0.46 | ||
| Q3 25 | $-1.55 | $0.10 | ||
| Q2 25 | $0.86 | $-0.01 | ||
| Q1 25 | $0.85 | $-0.23 | ||
| Q4 24 | $1.06 | $0.40 | ||
| Q3 24 | $1.28 | $-0.02 | ||
| Q2 24 | $0.76 | $-0.10 | ||
| Q1 24 | $0.90 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $137.5M |
| Total DebtLower is stronger | $443.2M | — |
| Stockholders' EquityBook value | $732.1M | $354.6M |
| Total Assets | $6.4B | $488.0M |
| Debt / EquityLower = less leverage | 0.61× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $137.5M | ||
| Q3 25 | — | $135.4M | ||
| Q2 25 | — | $116.9M | ||
| Q1 25 | — | $112.9M | ||
| Q4 24 | — | $116.2M | ||
| Q3 24 | — | $101.7M | ||
| Q2 24 | — | $102.5M | ||
| Q1 24 | — | $110.6M |
| Q4 25 | $443.2M | — | ||
| Q3 25 | $486.9M | — | ||
| Q2 25 | $448.4M | — | ||
| Q1 25 | $376.9M | — | ||
| Q4 24 | $312.8M | — | ||
| Q3 24 | $437.5M | — | ||
| Q2 24 | $391.7M | — | ||
| Q1 24 | $367.1M | — |
| Q4 25 | $732.1M | $354.6M | ||
| Q3 25 | $711.9M | $321.9M | ||
| Q2 25 | $635.6M | $306.8M | ||
| Q1 25 | $617.3M | $295.5M | ||
| Q4 24 | $592.9M | $292.0M | ||
| Q3 24 | $504.0M | $257.5M | ||
| Q2 24 | $461.4M | $243.0M | ||
| Q1 24 | $456.8M | $233.9M |
| Q4 25 | $6.4B | $488.0M | ||
| Q3 25 | $6.4B | $453.3M | ||
| Q2 25 | $5.4B | $435.6M | ||
| Q1 25 | $5.4B | $424.6M | ||
| Q4 24 | $5.3B | $432.7M | ||
| Q3 24 | $5.4B | $390.4M | ||
| Q2 24 | $5.2B | $376.8M | ||
| Q1 24 | $5.2B | $356.7M |
| Q4 25 | 0.61× | — | ||
| Q3 25 | 0.68× | — | ||
| Q2 25 | 0.71× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.87× | — | ||
| Q2 24 | 0.85× | — | ||
| Q1 24 | 0.80× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $51.4M | $15.0M |
| Free Cash FlowOCF − Capex | $38.1M | $12.8M |
| FCF MarginFCF / Revenue | 60.0% | 13.8% |
| Capex IntensityCapex / Revenue | 20.9% | 2.4% |
| Cash ConversionOCF / Net Profit | 2.33× | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $88.8M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $51.4M | $15.0M | ||
| Q3 25 | $8.5M | $22.1M | ||
| Q2 25 | $28.3M | $8.2M | ||
| Q1 25 | $21.7M | $6.6M | ||
| Q4 24 | $73.8M | $22.2M | ||
| Q3 24 | $23.5M | $10.2M | ||
| Q2 24 | $16.0M | $18.5M | ||
| Q1 24 | $12.6M | $7.2M |
| Q4 25 | $38.1M | $12.8M | ||
| Q3 25 | $4.5M | $19.5M | ||
| Q2 25 | $26.0M | $81.0K | ||
| Q1 25 | $20.2M | $-7.6M | ||
| Q4 24 | $65.4M | $8.5M | ||
| Q3 24 | $19.7M | $-9.2M | ||
| Q2 24 | $15.2M | $1.8M | ||
| Q1 24 | $10.6M | $-6.8M |
| Q4 25 | 60.0% | 13.8% | ||
| Q3 25 | 24.7% | 28.8% | ||
| Q2 25 | 44.5% | 0.1% | ||
| Q1 25 | 33.3% | -14.5% | ||
| Q4 24 | 112.1% | 11.2% | ||
| Q3 24 | 35.6% | -15.9% | ||
| Q2 24 | 27.4% | 3.4% | ||
| Q1 24 | 19.0% | -13.3% |
| Q4 25 | 20.9% | 2.4% | ||
| Q3 25 | 22.3% | 3.9% | ||
| Q2 25 | 3.9% | 12.9% | ||
| Q1 25 | 2.4% | 27.0% | ||
| Q4 24 | 14.6% | 18.3% | ||
| Q3 24 | 6.8% | 33.5% | ||
| Q2 24 | 1.5% | 31.8% | ||
| Q1 24 | 3.6% | 27.3% |
| Q4 25 | 2.33× | 0.65× | ||
| Q3 25 | — | 4.35× | ||
| Q2 25 | 1.85× | — | ||
| Q1 25 | 1.44× | — | ||
| Q4 24 | 4.35× | 1.12× | ||
| Q3 24 | 1.18× | — | ||
| Q2 24 | 1.37× | — | ||
| Q1 24 | 0.90× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EQBK
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
